皮膚および全身リーシュマニア症の世界市場

皮膚および全身リーシュマニア症の世界市場は2030年までに3億9,310万米ドルに達する見込み

2024年に3億5,480万米ドルと推定される皮膚および全身リーシュマニア症の世界市場は、2030年には3億9,310万米ドルに達すると予測され、分析期間2024～2030年のCAGRは1.7%で成長すると予測されます。本レポートで分析したセグメントの1つである5価抗真菌薬剤クラス別は、CAGR 1.4%を記録し、分析期間終了時には2億2,050万米ドルに達すると予測されます。抗真菌薬クラス別セグメントの成長率は、分析期間中CAGR 2.1%と推定されます。

米国市場は9,670万米ドルと推定、中国はCAGR 3.2％で成長予測

米国の皮膚および全身リーシュマニア症市場は2024年に9,670万米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに7,210万米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは3.2%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ0.7％と1.4％と予測されています。欧州では、ドイツがCAGR 1.0%で成長すると予測されています。

世界の皮膚および全身リーシュマニア症市場- 主要動向と促進要因まとめ

なぜリーシュマニア症は世界の感染症管理において重要な重点分野なのか？

皮膚および全身リーシュマニア症は、リーシュマニア属の原虫寄生によって引き起こされ、感染したサンドフライに咬まれることで感染する、顧みられない熱帯病として最も課題となっている2つの疾患の代表です。皮膚リーシュマニア症は主に皮膚を侵し、潰瘍や醜い病変を引き起こすが、全身性リーシュマニア症または内臓リーシュマニア症（カラアザールとしても知られる）は、はるかに重篤で、肝臓、脾臓、骨髄などの内臓に影響を及ぼし、放置すると致命的となります。どちらの病型も、特に南アジア、アフリカ、ラテンアメリカ、中東などの低・中所得地域の人々に偏って影響を及ぼしています。

リーシュマニア症は90カ国以上に蔓延しているにもかかわらず、診断が不十分で資金も不足しています。劣悪な衛生環境、気候変動、人の移動、森林伐採がリーシュマニアの感染を加速させています。治療抵抗性株の増加、HIVとの重複感染、有効で安全かつ安価な治療法の限られた利用可能性から、診断ツールの改善、新規治療薬、予防戦略の緊急性が強調されています。公衆衛生機関や国際機関が顧みられない熱帯病の制圧に力を入れる中、医療・製薬業界は革新的なリーシュマニア症治療法の研究開発を再開し、これに応えています。

どのような治療アプローチと診断の進歩が疾病管理を再構築しているのか？

皮膚および全身リーシュマニア症に対する現在の治療選択肢には、抗植物性化合物、アムホテリシンB、ミルテホシン、パロモマイシンなどがあります。しかし、これらの治療法の多くは、毒性、治療期間の長さ、非経口投与、寄生虫の種類によって効果が異なるなど、大きな制約があります。全身性リーシュマニア症では、リポソーム型アムホテリシンBが、より優れた安全性プロファイルのため、特定の地域では好ましい選択肢となっているが、コストと物流の障壁により、依然としてアクセスは制限されています。有効性を高め、耐性を減らし、治療レジメンを短縮するために、併用療法が検討されています。

診断の面では、従来の寄生虫学的手法に加え、分子生物学的診断法（PCR法）や迅速抗原検出検査が導入され、早期診断と治療モニタリングが改善されつつあります。皮膚型では、皮膚塗抹顕微鏡検査や病理組織学的検査が依然として広く用いられているが、農村部の医療システムでは、より新しいポイントオブケア診断キットが普及しつつあります。研究はまた、ワクチン候補の同定や、標的を改善し副作用を軽減するリポソーム製剤や経皮パッチなどの新規ドラッグデリバリーシステムの開発にも重点を置いています。

疾病負担の影響を最も受ける地域と患者層は？

皮膚リーシュマニア症の有病率が最も高いのは、アフガニスタン、シリア、ブラジル、イラン、パキスタンであり、社会的不安定、媒介蚊の増殖、医療インフラの制限が病気の蔓延を悪化させています。臓器リーシュマニア症はインド、スーダン、エチオピア、バングラデシュで流行しており、特に医療へのアクセスが低く、貧しい農村部の人々に影響を及ぼしています。小児、免疫不全者、HIV重複感染者は特に内臓型リーシュマニア症に罹患しやすく、致死率が高く、治療成績も悪いです。

難民、労働移民、紛争地域の住民は、疾病対策プログラムの崩壊やサンドフライの生息地への曝露の増加により、ますます影響を受けています。また、森林地帯や農業地帯に都市が拡大することで、人と媒介虫の接点が増え、感染がさらに拡大しています。集団薬剤投与プログラム、地域社会の意識向上キャンペーン、媒介虫対策は、こうした感染率の高い地域では依然として重要ですが、資金、診断法、ロジスティクスの課題が依然として影響力を制限しています。

皮膚および全身リーシュマニア症治療市場の成長を促す要因とは？

皮膚および全身リーシュマニア症市場の成長は、相互に関連するいくつかの公衆衛生、医薬品、環境要因によって牽引されています。顧みられない熱帯病に対する世界の関心の高まりと、非政府組織や公衆衛生機関からの資金提供の増加は、より効果的で利用しやすい治療法の研究に拍車をかけています。経口治療薬、ナノ製剤、免疫調整剤など、薬剤候補のパイプラインの拡大により、より安全で、より短期間で、よりスケーラブルな治療レジメンへの新たな道が開かれつつあります。

また、官民パートナーシップの開発支援により、共同での医薬品開発、流通、データ共有が可能になり、蔓延するニーズに対応できるようになってきています。リーシュマニア症は、HIVや栄養失調など他の公衆衛生問題と密接に関連しているため、統合的な医療対応や広範なスクリーニング・イニシアチブが推進されています。最後に、媒介蚊のサーベイランス、気候に基づくリスクマッピング、モバイル診断の革新は、早期発見と介入能力を向上させています。このような動きは、公衆衛生上の脅威としてのリーシュマニア症撲滅へのコミットメントの高まりと、治療・診断イノベーションの市場機会の拡大を裏付けています。

セグメント

薬剤クラス（五価抗真菌薬クラス、抗真菌薬クラス、抗レジスマニア薬／抗菌薬クラス）、投与ルート（経口ルート、注射ルート、局所ルート）、適応症（皮膚リーシュマニア症適応症、粘膜リーシュマニア症適応症、内臓リーシュマニア症適応症）、流通チャネル（病院薬局、小売薬局、ドラッグストア、オンライン流通チャネル）

調査対象企業の例（注目の41社）

• Albert David Ltd.
• Bayer AG
• Biocon Limited
• BioLineRx Ltd.
• Bristol-Myers Squibb
• Camurus AB
• DNDi
• Eisai Co., Ltd.
• Endo Pharmaceuticals
• Gilead Sciences, Inc.
• GlaxoSmithKline plc
• Janssen Global Services
• Jubilant Life Sciences
• Knight Therapeutics Inc.
• Novartis AG
• Pfizer Inc.
• Protalix BioTherapeutics
• Sanofi
• Takeda Pharmaceutical
• United Biotech Pvt. Ltd.

AI統合

私たちは、有効な専門家コンテンツとAIツールによって、市場情報と競合情報を変革しています。

Global Industry Analystsは、LLMや業界固有のSLMを照会する一般的な規範に従う代わりに、ビデオ記録、ブログ、検索エンジン調査、膨大な量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

• 市場概要
• 主要企業
• 市場動向と促進要因
• 世界市場の見通し

第3章 市場分析

• 米国
• カナダ
• 日本
• 中国
• 欧州
• フランス
• ドイツ
• イタリア
• 英国
• スペイン
• ロシア
• その他欧州
• アジア太平洋
• オーストラリア
• インド
• 韓国
• その他アジア太平洋地域
• ラテンアメリカ
• アルゼンチン
• ブラジル
• メキシコ
• その他ラテンアメリカ
• 中東
• イラン
• イスラエル
• サウジアラビア
• アラブ首長国連邦
• その他中東
• アフリカ

第4章 競合

Global Cutaneous and Systemic Leishmaniasis Market to Reach US$393.1 Million by 2030

The global market for Cutaneous and Systemic Leishmaniasis estimated at US$354.8 Million in the year 2024, is expected to reach US$393.1 Million by 2030, growing at a CAGR of 1.7% over the analysis period 2024-2030. Pentavalent Antimonials Drug Class, one of the segments analyzed in the report, is expected to record a 1.4% CAGR and reach US$220.5 Million by the end of the analysis period. Growth in the Antifungals Drug Class segment is estimated at 2.1% CAGR over the analysis period.

The U.S. Market is Estimated at US$96.7 Million While China is Forecast to Grow at 3.2% CAGR

The Cutaneous and Systemic Leishmaniasis market in the U.S. is estimated at US$96.7 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$72.1 Million by the year 2030 trailing a CAGR of 3.2% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 0.7% and 1.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.0% CAGR.

Global Cutaneous and Systemic Leishmaniasis Market - Key Trends & Drivers Summarized

Why Is Leishmaniasis a Critical Focus Area in Global Infectious Disease Management?

Cutaneous and systemic leishmaniasis represent two of the most challenging neglected tropical diseases, caused by protozoan parasites of the Leishmania genus, transmitted through the bite of infected sandflies. Cutaneous leishmaniasis primarily affects the skin, causing ulcers and disfiguring lesions, while systemic or visceral leishmaniasis-also known as kala-azar-is far more severe, impacting internal organs such as the liver, spleen, and bone marrow and can be fatal if left untreated. Both forms of the disease disproportionately affect populations in low- and middle-income regions, particularly in parts of South Asia, Africa, Latin America, and the Middle East.

Despite being endemic to over 90 countries, leishmaniasis remains underdiagnosed and underfunded. Poor sanitation, climate change, human migration, and deforestation are accelerating its transmission. The increasing incidence of treatment-resistant strains, coinfections with HIV, and the limited availability of effective, safe, and affordable therapies underscore the urgency for improved diagnostic tools, novel therapeutics, and preventive strategies. As public health agencies and global organizations intensify focus on controlling neglected tropical diseases, the medical and pharmaceutical sectors are responding with renewed R&D into innovative leishmaniasis treatments.

What Therapeutic Approaches and Diagnostic Advancements Are Reshaping Disease Management?

Current treatment options for cutaneous and systemic leishmaniasis include antimonial compounds, amphotericin B, miltefosine, and paromomycin. However, many of these therapies have significant limitations, including toxicity, lengthy treatment durations, parenteral administration, and variable efficacy across parasite species. In systemic leishmaniasis, liposomal amphotericin B has become a preferred option in certain regions due to better safety profiles, though access remains limited by cost and logistical barriers. Combination therapies are being explored to enhance efficacy, reduce resistance, and shorten treatment regimens.

On the diagnostic front, traditional parasitological methods are being supplemented with molecular diagnostics (e.g., PCR-based assays) and rapid antigen detection tests, improving early-stage diagnosis and treatment monitoring. In cutaneous forms, dermal smear microscopy and histopathological examinations remain widely used, though newer point-of-care diagnostic kits are gaining ground in rural health systems. Research is also focused on identifying vaccine candidates and developing novel drug delivery systems such as liposomal formulations and transdermal patches that offer improved targeting and reduced side effects.

Which Regions and Patient Segments Are Most Affected by the Disease Burden?

The highest prevalence of cutaneous leishmaniasis is found in Afghanistan, Syria, Brazil, Iran, and Pakistan, where social instability, vector proliferation, and limited healthcare infrastructure exacerbate disease spread. Visceral leishmaniasis remains endemic in India, Sudan, Ethiopia, and Bangladesh, particularly affecting impoverished rural populations with low access to healthcare. Children, immunocompromised individuals, and those co-infected with HIV are particularly vulnerable to visceral forms of the disease, with higher fatality rates and poorer treatment outcomes.

Refugee populations, labor migrants, and residents of conflict zones are increasingly affected due to the collapse of disease control programs and rising exposure to sandfly habitats. Urban expansion into forested or agricultural areas is also increasing the human-vector interface, further driving transmission. Mass drug administration programs, community awareness campaigns, and vector control initiatives remain critical in these high-burden areas, although challenges in funding, diagnostics, and logistics continue to limit impact.

What Factors Are Driving Growth in the Cutaneous and Systemic Leishmaniasis Treatment Market?

The growth in the cutaneous and systemic leishmaniasis market is driven by several interrelated public health, pharmaceutical, and environmental factors. Rising global attention to neglected tropical diseases and increasing funding from non-governmental organizations and public health agencies are fueling research into more effective and accessible treatment options. The expanding pipeline of drug candidates-including oral therapies, nano-formulations, and immunomodulators-is introducing new avenues for safer, shorter, and more scalable treatment regimens.

Growing support for public-private partnerships is enabling collaborative drug development, distribution, and data-sharing initiatives to address endemic needs. The intensifying intersection of leishmaniasis with other public health issues, such as HIV and malnutrition, is driving integrated healthcare responses and broader screening initiatives. Lastly, innovations in vector surveillance, climate-based risk mapping, and mobile diagnostics are improving early detection and intervention capabilities. These dynamics collectively underscore a growing commitment to eliminating leishmaniasis as a public health threat and expanding market opportunities for therapeutic and diagnostic innovation.

SCOPE OF STUDY:

The report analyzes the Cutaneous and Systemic Leishmaniasis market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Drug Class (Pentavalent Antimonials Drug Class, Antifungals Drug Class, Anti-Lesihmanial / Antimicrobials Drug Class); Administration Route (Oral Route, Injectable Route, Topical Route); Indication (Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication, Visceral Leishmaniasis Indication); Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Drug Stores, Online Distribution Channel)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 41 Featured) -

• Albert David Ltd.
• Bayer AG
• Biocon Limited
• BioLineRx Ltd.
• Bristol-Myers Squibb
• Camurus AB
• DNDi
• Eisai Co., Ltd.
• Endo Pharmaceuticals
• Gilead Sciences, Inc.
• GlaxoSmithKline plc
• Janssen Global Services
• Jubilant Life Sciences
• Knight Therapeutics Inc.
• Novartis AG
• Pfizer Inc.
• Protalix BioTherapeutics
• Sanofi
• Takeda Pharmaceutical
• United Biotech Pvt. Ltd.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Tariff Impact on Global Supply Chain Patterns
  • Cutaneous and Systemic Leishmaniasis - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Rising Prevalence in Endemic Regions Propels Global Demand for Leishmaniasis Diagnostics and Therapeutics
  • Expansion of Public Health Surveillance Initiatives Strengthens Case for Early Detection Solutions
  • Growing Investments in Tropical Disease Research Throws the Spotlight on Leishmaniasis Drug Development
  • Limited Treatment Access in Developing Regions Spurs Need for Affordable Therapeutic Options
  • Global Health NGO and Government Partnerships Accelerate Mass Screening and Awareness Campaigns
  • Emerging Drug Resistance Patterns in Leishmania Parasites Drive Innovation in Antileishmanial Compounds
  • Increased Adoption of Liposomal Amphotericin B Sustains Market for Targeted Systemic Therapies
  • Climate Change and Human Migration Expand Leishmaniasis Transmission Zones Globally
  • Demand for Point-of-Care Diagnostics Strengthens Market for Field-Deployable Detection Kits
  • Focus on Animal Reservoir Control Boosts Demand for Vector Control and Zoonotic Prevention Tools
  • R&D Advances in Vaccine Development Create Long-Term Market Opportunities
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Cutaneous and Systemic Leishmaniasis Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Cutaneous and Systemic Leishmaniasis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 4: World 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Pentavalent Antimonials Drug Class by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Pentavalent Antimonials Drug Class by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 7: World 16-Year Perspective for Pentavalent Antimonials Drug Class by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Antifungals Drug Class by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Antifungals Drug Class by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 10: World 16-Year Perspective for Antifungals Drug Class by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Anti-Lesihmanial / Antimicrobials Drug Class by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Anti-Lesihmanial / Antimicrobials Drug Class by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 13: World 16-Year Perspective for Anti-Lesihmanial / Antimicrobials Drug Class by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 16: World 16-Year Perspective for Hospital Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 19: World 16-Year Perspective for Retail Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Drug Stores by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Drug Stores by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 22: World 16-Year Perspective for Drug Stores by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Online Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Online Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 25: World 16-Year Perspective for Online Distribution Channel by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Oral Route by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 27: World Historic Review for Oral Route by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 28: World 16-Year Perspective for Oral Route by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 29: World Recent Past, Current & Future Analysis for Injectable Route by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 30: World Historic Review for Injectable Route by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 31: World 16-Year Perspective for Injectable Route by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 32: World Recent Past, Current & Future Analysis for Topical Route by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 33: World Historic Review for Topical Route by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 34: World 16-Year Perspective for Topical Route by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 35: World Recent Past, Current & Future Analysis for Cutaneous Leishmaniasis Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 36: World Historic Review for Cutaneous Leishmaniasis Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 37: World 16-Year Perspective for Cutaneous Leishmaniasis Indication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 38: World Recent Past, Current & Future Analysis for Mucosal Leishmaniasis Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 39: World Historic Review for Mucosal Leishmaniasis Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 40: World 16-Year Perspective for Mucosal Leishmaniasis Indication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 41: World Recent Past, Current & Future Analysis for Visceral Leishmaniasis Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 42: World Historic Review for Visceral Leishmaniasis Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 43: World 16-Year Perspective for Visceral Leishmaniasis Indication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Cutaneous and Systemic Leishmaniasis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 44: USA Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Drug Class - Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 45: USA Historic Review for Cutaneous and Systemic Leishmaniasis by Drug Class - Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 46: USA 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Drug Class - Percentage Breakdown of Value Sales for Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class for the Years 2014, 2025 & 2030
  • TABLE 47: USA Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 48: USA Historic Review for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 49: USA 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel for the Years 2014, 2025 & 2030
  • TABLE 50: USA Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Administration Route - Oral Route, Injectable Route and Topical Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 51: USA Historic Review for Cutaneous and Systemic Leishmaniasis by Administration Route - Oral Route, Injectable Route and Topical Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 52: USA 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Administration Route - Percentage Breakdown of Value Sales for Oral Route, Injectable Route and Topical Route for the Years 2014, 2025 & 2030
  • TABLE 53: USA Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Indication - Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 54: USA Historic Review for Cutaneous and Systemic Leishmaniasis by Indication - Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 55: USA 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Indication - Percentage Breakdown of Value Sales for Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication for the Years 2014, 2025 & 2030
• CANADA
  • TABLE 56: Canada Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Drug Class - Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 57: Canada Historic Review for Cutaneous and Systemic Leishmaniasis by Drug Class - Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 58: Canada 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Drug Class - Percentage Breakdown of Value Sales for Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class for the Years 2014, 2025 & 2030
  • TABLE 59: Canada Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 60: Canada Historic Review for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 61: Canada 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel for the Years 2014, 2025 & 2030
  • TABLE 62: Canada Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Administration Route - Oral Route, Injectable Route and Topical Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 63: Canada Historic Review for Cutaneous and Systemic Leishmaniasis by Administration Route - Oral Route, Injectable Route and Topical Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 64: Canada 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Administration Route - Percentage Breakdown of Value Sales for Oral Route, Injectable Route and Topical Route for the Years 2014, 2025 & 2030
  • TABLE 65: Canada Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Indication - Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 66: Canada Historic Review for Cutaneous and Systemic Leishmaniasis by Indication - Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 67: Canada 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Indication - Percentage Breakdown of Value Sales for Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication for the Years 2014, 2025 & 2030
• JAPAN
  • Cutaneous and Systemic Leishmaniasis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 68: Japan Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Drug Class - Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 69: Japan Historic Review for Cutaneous and Systemic Leishmaniasis by Drug Class - Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 70: Japan 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Drug Class - Percentage Breakdown of Value Sales for Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class for the Years 2014, 2025 & 2030
  • TABLE 71: Japan Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 72: Japan Historic Review for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 73: Japan 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel for the Years 2014, 2025 & 2030
  • TABLE 74: Japan Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Administration Route - Oral Route, Injectable Route and Topical Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 75: Japan Historic Review for Cutaneous and Systemic Leishmaniasis by Administration Route - Oral Route, Injectable Route and Topical Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 76: Japan 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Administration Route - Percentage Breakdown of Value Sales for Oral Route, Injectable Route and Topical Route for the Years 2014, 2025 & 2030
  • TABLE 77: Japan Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Indication - Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 78: Japan Historic Review for Cutaneous and Systemic Leishmaniasis by Indication - Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 79: Japan 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Indication - Percentage Breakdown of Value Sales for Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication for the Years 2014, 2025 & 2030
• CHINA
  • Cutaneous and Systemic Leishmaniasis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 80: China Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Drug Class - Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 81: China Historic Review for Cutaneous and Systemic Leishmaniasis by Drug Class - Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 82: China 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Drug Class - Percentage Breakdown of Value Sales for Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class for the Years 2014, 2025 & 2030
  • TABLE 83: China Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 84: China Historic Review for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 85: China 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel for the Years 2014, 2025 & 2030
  • TABLE 86: China Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Administration Route - Oral Route, Injectable Route and Topical Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 87: China Historic Review for Cutaneous and Systemic Leishmaniasis by Administration Route - Oral Route, Injectable Route and Topical Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 88: China 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Administration Route - Percentage Breakdown of Value Sales for Oral Route, Injectable Route and Topical Route for the Years 2014, 2025 & 2030
  • TABLE 89: China Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Indication - Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 90: China Historic Review for Cutaneous and Systemic Leishmaniasis by Indication - Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 91: China 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Indication - Percentage Breakdown of Value Sales for Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication for the Years 2014, 2025 & 2030
• EUROPE
  • Cutaneous and Systemic Leishmaniasis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 92: Europe Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 93: Europe Historic Review for Cutaneous and Systemic Leishmaniasis by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 94: Europe 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
  • TABLE 95: Europe Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Drug Class - Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 96: Europe Historic Review for Cutaneous and Systemic Leishmaniasis by Drug Class - Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 97: Europe 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Drug Class - Percentage Breakdown of Value Sales for Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class for the Years 2014, 2025 & 2030
  • TABLE 98: Europe Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 99: Europe Historic Review for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 100: Europe 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel for the Years 2014, 2025 & 2030
  • TABLE 101: Europe Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Administration Route - Oral Route, Injectable Route and Topical Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 102: Europe Historic Review for Cutaneous and Systemic Leishmaniasis by Administration Route - Oral Route, Injectable Route and Topical Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 103: Europe 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Administration Route - Percentage Breakdown of Value Sales for Oral Route, Injectable Route and Topical Route for the Years 2014, 2025 & 2030
  • TABLE 104: Europe Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Indication - Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 105: Europe Historic Review for Cutaneous and Systemic Leishmaniasis by Indication - Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 106: Europe 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Indication - Percentage Breakdown of Value Sales for Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication for the Years 2014, 2025 & 2030
• FRANCE
  • Cutaneous and Systemic Leishmaniasis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 107: France Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Drug Class - Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 108: France Historic Review for Cutaneous and Systemic Leishmaniasis by Drug Class - Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 109: France 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Drug Class - Percentage Breakdown of Value Sales for Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class for the Years 2014, 2025 & 2030
  • TABLE 110: France Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 111: France Historic Review for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 112: France 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel for the Years 2014, 2025 & 2030
  • TABLE 113: France Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Administration Route - Oral Route, Injectable Route and Topical Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 114: France Historic Review for Cutaneous and Systemic Leishmaniasis by Administration Route - Oral Route, Injectable Route and Topical Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 115: France 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Administration Route - Percentage Breakdown of Value Sales for Oral Route, Injectable Route and Topical Route for the Years 2014, 2025 & 2030
  • TABLE 116: France Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Indication - Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 117: France Historic Review for Cutaneous and Systemic Leishmaniasis by Indication - Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 118: France 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Indication - Percentage Breakdown of Value Sales for Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication for the Years 2014, 2025 & 2030
• GERMANY
  • Cutaneous and Systemic Leishmaniasis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 119: Germany Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Drug Class - Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 120: Germany Historic Review for Cutaneous and Systemic Leishmaniasis by Drug Class - Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 121: Germany 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Drug Class - Percentage Breakdown of Value Sales for Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class for the Years 2014, 2025 & 2030
  • TABLE 122: Germany Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 123: Germany Historic Review for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 124: Germany 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel for the Years 2014, 2025 & 2030
  • TABLE 125: Germany Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Administration Route - Oral Route, Injectable Route and Topical Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 126: Germany Historic Review for Cutaneous and Systemic Leishmaniasis by Administration Route - Oral Route, Injectable Route and Topical Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 127: Germany 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Administration Route - Percentage Breakdown of Value Sales for Oral Route, Injectable Route and Topical Route for the Years 2014, 2025 & 2030
  • TABLE 128: Germany Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Indication - Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 129: Germany Historic Review for Cutaneous and Systemic Leishmaniasis by Indication - Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 130: Germany 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Indication - Percentage Breakdown of Value Sales for Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication for the Years 2014, 2025 & 2030
• ITALY
  • TABLE 131: Italy Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Drug Class - Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 132: Italy Historic Review for Cutaneous and Systemic Leishmaniasis by Drug Class - Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 133: Italy 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Drug Class - Percentage Breakdown of Value Sales for Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class for the Years 2014, 2025 & 2030
  • TABLE 134: Italy Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 135: Italy Historic Review for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 136: Italy 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel for the Years 2014, 2025 & 2030
  • TABLE 137: Italy Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Administration Route - Oral Route, Injectable Route and Topical Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 138: Italy Historic Review for Cutaneous and Systemic Leishmaniasis by Administration Route - Oral Route, Injectable Route and Topical Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 139: Italy 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Administration Route - Percentage Breakdown of Value Sales for Oral Route, Injectable Route and Topical Route for the Years 2014, 2025 & 2030
  • TABLE 140: Italy Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Indication - Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 141: Italy Historic Review for Cutaneous and Systemic Leishmaniasis by Indication - Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 142: Italy 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Indication - Percentage Breakdown of Value Sales for Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication for the Years 2014, 2025 & 2030
• UNITED KINGDOM
  • Cutaneous and Systemic Leishmaniasis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 143: UK Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Drug Class - Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 144: UK Historic Review for Cutaneous and Systemic Leishmaniasis by Drug Class - Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 145: UK 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Drug Class - Percentage Breakdown of Value Sales for Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class for the Years 2014, 2025 & 2030
  • TABLE 146: UK Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 147: UK Historic Review for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 148: UK 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel for the Years 2014, 2025 & 2030
  • TABLE 149: UK Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Administration Route - Oral Route, Injectable Route and Topical Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 150: UK Historic Review for Cutaneous and Systemic Leishmaniasis by Administration Route - Oral Route, Injectable Route and Topical Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 151: UK 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Administration Route - Percentage Breakdown of Value Sales for Oral Route, Injectable Route and Topical Route for the Years 2014, 2025 & 2030
  • TABLE 152: UK Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Indication - Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 153: UK Historic Review for Cutaneous and Systemic Leishmaniasis by Indication - Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 154: UK 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Indication - Percentage Breakdown of Value Sales for Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication for the Years 2014, 2025 & 2030
• SPAIN
  • TABLE 155: Spain Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Drug Class - Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 156: Spain Historic Review for Cutaneous and Systemic Leishmaniasis by Drug Class - Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 157: Spain 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Drug Class - Percentage Breakdown of Value Sales for Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class for the Years 2014, 2025 & 2030
  • TABLE 158: Spain Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 159: Spain Historic Review for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 160: Spain 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel for the Years 2014, 2025 & 2030
  • TABLE 161: Spain Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Administration Route - Oral Route, Injectable Route and Topical Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 162: Spain Historic Review for Cutaneous and Systemic Leishmaniasis by Administration Route - Oral Route, Injectable Route and Topical Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 163: Spain 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Administration Route - Percentage Breakdown of Value Sales for Oral Route, Injectable Route and Topical Route for the Years 2014, 2025 & 2030
  • TABLE 164: Spain Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Indication - Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 165: Spain Historic Review for Cutaneous and Systemic Leishmaniasis by Indication - Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 166: Spain 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Indication - Percentage Breakdown of Value Sales for Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication for the Years 2014, 2025 & 2030
• RUSSIA
  • TABLE 167: Russia Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Drug Class - Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 168: Russia Historic Review for Cutaneous and Systemic Leishmaniasis by Drug Class - Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 169: Russia 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Drug Class - Percentage Breakdown of Value Sales for Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class for the Years 2014, 2025 & 2030
  • TABLE 170: Russia Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 171: Russia Historic Review for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 172: Russia 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel for the Years 2014, 2025 & 2030
  • TABLE 173: Russia Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Administration Route - Oral Route, Injectable Route and Topical Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 174: Russia Historic Review for Cutaneous and Systemic Leishmaniasis by Administration Route - Oral Route, Injectable Route and Topical Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 175: Russia 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Administration Route - Percentage Breakdown of Value Sales for Oral Route, Injectable Route and Topical Route for the Years 2014, 2025 & 2030
  • TABLE 176: Russia Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Indication - Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 177: Russia Historic Review for Cutaneous and Systemic Leishmaniasis by Indication - Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 178: Russia 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Indication - Percentage Breakdown of Value Sales for Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication for the Years 2014, 2025 & 2030
• REST OF EUROPE
  • TABLE 179: Rest of Europe Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Drug Class - Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 180: Rest of Europe Historic Review for Cutaneous and Systemic Leishmaniasis by Drug Class - Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 181: Rest of Europe 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Drug Class - Percentage Breakdown of Value Sales for Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class for the Years 2014, 2025 & 2030
  • TABLE 182: Rest of Europe Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 183: Rest of Europe Historic Review for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 184: Rest of Europe 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel for the Years 2014, 2025 & 2030
  • TABLE 185: Rest of Europe Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Administration Route - Oral Route, Injectable Route and Topical Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 186: Rest of Europe Historic Review for Cutaneous and Systemic Leishmaniasis by Administration Route - Oral Route, Injectable Route and Topical Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 187: Rest of Europe 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Administration Route - Percentage Breakdown of Value Sales for Oral Route, Injectable Route and Topical Route for the Years 2014, 2025 & 2030
  • TABLE 188: Rest of Europe Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Indication - Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 189: Rest of Europe Historic Review for Cutaneous and Systemic Leishmaniasis by Indication - Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 190: Rest of Europe 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Indication - Percentage Breakdown of Value Sales for Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication for the Years 2014, 2025 & 2030
• ASIA-PACIFIC
  • Cutaneous and Systemic Leishmaniasis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 191: Asia-Pacific Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 192: Asia-Pacific Historic Review for Cutaneous and Systemic Leishmaniasis by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 193: Asia-Pacific 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
  • TABLE 194: Asia-Pacific Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Drug Class - Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 195: Asia-Pacific Historic Review for Cutaneous and Systemic Leishmaniasis by Drug Class - Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 196: Asia-Pacific 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Drug Class - Percentage Breakdown of Value Sales for Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class for the Years 2014, 2025 & 2030
  • TABLE 197: Asia-Pacific Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 198: Asia-Pacific Historic Review for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 199: Asia-Pacific 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel for the Years 2014, 2025 & 2030
  • TABLE 200: Asia-Pacific Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Administration Route - Oral Route, Injectable Route and Topical Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 201: Asia-Pacific Historic Review for Cutaneous and Systemic Leishmaniasis by Administration Route - Oral Route, Injectable Route and Topical Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 202: Asia-Pacific 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Administration Route - Percentage Breakdown of Value Sales for Oral Route, Injectable Route and Topical Route for the Years 2014, 2025 & 2030
  • TABLE 203: Asia-Pacific Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Indication - Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 204: Asia-Pacific Historic Review for Cutaneous and Systemic Leishmaniasis by Indication - Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 205: Asia-Pacific 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Indication - Percentage Breakdown of Value Sales for Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication for the Years 2014, 2025 & 2030
• AUSTRALIA
  • Cutaneous and Systemic Leishmaniasis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
  • TABLE 206: Australia Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Drug Class - Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 207: Australia Historic Review for Cutaneous and Systemic Leishmaniasis by Drug Class - Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 208: Australia 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Drug Class - Percentage Breakdown of Value Sales for Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class for the Years 2014, 2025 & 2030
  • TABLE 209: Australia Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 210: Australia Historic Review for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 211: Australia 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel for the Years 2014, 2025 & 2030
  • TABLE 212: Australia Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Administration Route - Oral Route, Injectable Route and Topical Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 213: Australia Historic Review for Cutaneous and Systemic Leishmaniasis by Administration Route - Oral Route, Injectable Route and Topical Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 214: Australia 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Administration Route - Percentage Breakdown of Value Sales for Oral Route, Injectable Route and Topical Route for the Years 2014, 2025 & 2030
  • TABLE 215: Australia Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Indication - Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 216: Australia Historic Review for Cutaneous and Systemic Leishmaniasis by Indication - Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 217: Australia 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Indication - Percentage Breakdown of Value Sales for Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication for the Years 2014, 2025 & 2030
• INDIA
  • Cutaneous and Systemic Leishmaniasis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
  • TABLE 218: India Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Drug Class - Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 219: India Historic Review for Cutaneous and Systemic Leishmaniasis by Drug Class - Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 220: India 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Drug Class - Percentage Breakdown of Value Sales for Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class for the Years 2014, 2025 & 2030
  • TABLE 221: India Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 222: India Historic Review for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 223: India 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel for the Years 2014, 2025 & 2030
  • TABLE 224: India Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Administration Route - Oral Route, Injectable Route and Topical Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 225: India Historic Review for Cutaneous and Systemic Leishmaniasis by Administration Route - Oral Route, Injectable Route and Topical Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 226: India 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Administration Route - Percentage Breakdown of Value Sales for Oral Route, Injectable Route and Topical Route for the Years 2014, 2025 & 2030
  • TABLE 227: India Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Indication - Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 228: India Historic Review for Cutaneous and Systemic Leishmaniasis by Indication - Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 229: India 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Indication - Percentage Breakdown of Value Sales for Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication for the Years 2014, 2025 & 2030
• SOUTH KOREA
  • TABLE 230: South Korea Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Drug Class - Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 231: South Korea Historic Review for Cutaneous and Systemic Leishmaniasis by Drug Class - Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 232: South Korea 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Drug Class - Percentage Breakdown of Value Sales for Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class for the Years 2014, 2025 & 2030
  • TABLE 233: South Korea Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 234: South Korea Historic Review for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 235: South Korea 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel for the Years 2014, 2025 & 2030
  • TABLE 236: South Korea Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Administration Route - Oral Route, Injectable Route and Topical Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 237: South Korea Historic Review for Cutaneous and Systemic Leishmaniasis by Administration Route - Oral Route, Injectable Route and Topical Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 238: South Korea 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Administration Route - Percentage Breakdown of Value Sales for Oral Route, Injectable Route and Topical Route for the Years 2014, 2025 & 2030
  • TABLE 239: South Korea Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Indication - Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 240: South Korea Historic Review for Cutaneous and Systemic Leishmaniasis by Indication - Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 241: South Korea 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Indication - Percentage Breakdown of Value Sales for Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication for the Years 2014, 2025 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 242: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Drug Class - Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 243: Rest of Asia-Pacific Historic Review for Cutaneous and Systemic Leishmaniasis by Drug Class - Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 244: Rest of Asia-Pacific 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Drug Class - Percentage Breakdown of Value Sales for Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class for the Years 2014, 2025 & 2030
  • TABLE 245: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 246: Rest of Asia-Pacific Historic Review for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 247: Rest of Asia-Pacific 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel for the Years 2014, 2025 & 2030
  • TABLE 248: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Administration Route - Oral Route, Injectable Route and Topical Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 249: Rest of Asia-Pacific Historic Review for Cutaneous and Systemic Leishmaniasis by Administration Route - Oral Route, Injectable Route and Topical Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 250: Rest of Asia-Pacific 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Administration Route - Percentage Breakdown of Value Sales for Oral Route, Injectable Route and Topical Route for the Years 2014, 2025 & 2030
  • TABLE 251: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Indication - Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 252: Rest of Asia-Pacific Historic Review for Cutaneous and Systemic Leishmaniasis by Indication - Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 253: Rest of Asia-Pacific 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Indication - Percentage Breakdown of Value Sales for Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication for the Years 2014, 2025 & 2030
• LATIN AMERICA
  • Cutaneous and Systemic Leishmaniasis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
  • TABLE 254: Latin America Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 255: Latin America Historic Review for Cutaneous and Systemic Leishmaniasis by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 256: Latin America 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
  • TABLE 257: Latin America Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Drug Class - Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 258: Latin America Historic Review for Cutaneous and Systemic Leishmaniasis by Drug Class - Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 259: Latin America 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Drug Class - Percentage Breakdown of Value Sales for Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class for the Years 2014, 2025 & 2030
  • TABLE 260: Latin America Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 261: Latin America Historic Review for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 262: Latin America 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel for the Years 2014, 2025 & 2030
  • TABLE 263: Latin America Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Administration Route - Oral Route, Injectable Route and Topical Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 264: Latin America Historic Review for Cutaneous and Systemic Leishmaniasis by Administration Route - Oral Route, Injectable Route and Topical Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 265: Latin America 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Administration Route - Percentage Breakdown of Value Sales for Oral Route, Injectable Route and Topical Route for the Years 2014, 2025 & 2030
  • TABLE 266: Latin America Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Indication - Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 267: Latin America Historic Review for Cutaneous and Systemic Leishmaniasis by Indication - Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 268: Latin America 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Indication - Percentage Breakdown of Value Sales for Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication for the Years 2014, 2025 & 2030
• ARGENTINA
  • TABLE 269: Argentina Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Drug Class - Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 270: Argentina Historic Review for Cutaneous and Systemic Leishmaniasis by Drug Class - Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 271: Argentina 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Drug Class - Percentage Breakdown of Value Sales for Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class for the Years 2014, 2025 & 2030
  • TABLE 272: Argentina Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 273: Argentina Historic Review for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 274: Argentina 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel for the Years 2014, 2025 & 2030
  • TABLE 275: Argentina Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Administration Route - Oral Route, Injectable Route and Topical Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 276: Argentina Historic Review for Cutaneous and Systemic Leishmaniasis by Administration Route - Oral Route, Injectable Route and Topical Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 277: Argentina 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Administration Route - Percentage Breakdown of Value Sales for Oral Route, Injectable Route and Topical Route for the Years 2014, 2025 & 2030
  • TABLE 278: Argentina Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Indication - Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 279: Argentina Historic Review for Cutaneous and Systemic Leishmaniasis by Indication - Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 280: Argentina 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Indication - Percentage Breakdown of Value Sales for Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication for the Years 2014, 2025 & 2030
• BRAZIL
  • TABLE 281: Brazil Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Drug Class - Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 282: Brazil Historic Review for Cutaneous and Systemic Leishmaniasis by Drug Class - Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 283: Brazil 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Drug Class - Percentage Breakdown of Value Sales for Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class for the Years 2014, 2025 & 2030
  • TABLE 284: Brazil Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 285: Brazil Historic Review for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 286: Brazil 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel for the Years 2014, 2025 & 2030
  • TABLE 287: Brazil Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Administration Route - Oral Route, Injectable Route and Topical Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 288: Brazil Historic Review for Cutaneous and Systemic Leishmaniasis by Administration Route - Oral Route, Injectable Route and Topical Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 289: Brazil 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Administration Route - Percentage Breakdown of Value Sales for Oral Route, Injectable Route and Topical Route for the Years 2014, 2025 & 2030
  • TABLE 290: Brazil Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Indication - Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 291: Brazil Historic Review for Cutaneous and Systemic Leishmaniasis by Indication - Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 292: Brazil 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Indication - Percentage Breakdown of Value Sales for Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication for the Years 2014, 2025 & 2030
• MEXICO
  • TABLE 293: Mexico Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Drug Class - Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 294: Mexico Historic Review for Cutaneous and Systemic Leishmaniasis by Drug Class - Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 295: Mexico 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Drug Class - Percentage Breakdown of Value Sales for Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class for the Years 2014, 2025 & 2030
  • TABLE 296: Mexico Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 297: Mexico Historic Review for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 298: Mexico 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel for the Years 2014, 2025 & 2030
  • TABLE 299: Mexico Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Administration Route - Oral Route, Injectable Route and Topical Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 300: Mexico Historic Review for Cutaneous and Systemic Leishmaniasis by Administration Route - Oral Route, Injectable Route and Topical Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 301: Mexico 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Administration Route - Percentage Breakdown of Value Sales for Oral Route, Injectable Route and Topical Route for the Years 2014, 2025 & 2030
  • TABLE 302: Mexico Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Indication - Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 303: Mexico Historic Review for Cutaneous and Systemic Leishmaniasis by Indication - Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 304: Mexico 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Indication - Percentage Breakdown of Value Sales for Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication for the Years 2014, 2025 & 2030
• REST OF LATIN AMERICA
  • TABLE 305: Rest of Latin America Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Drug Class - Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 306: Rest of Latin America Historic Review for Cutaneous and Systemic Leishmaniasis by Drug Class - Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 307: Rest of Latin America 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Drug Class - Percentage Breakdown of Value Sales for Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class for the Years 2014, 2025 & 2030
  • TABLE 308: Rest of Latin America Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 309: Rest of Latin America Historic Review for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 310: Rest of Latin America 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel for the Years 2014, 2025 & 2030
  • TABLE 311: Rest of Latin America Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Administration Route - Oral Route, Injectable Route and Topical Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 312: Rest of Latin America Historic Review for Cutaneous and Systemic Leishmaniasis by Administration Route - Oral Route, Injectable Route and Topical Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 313: Rest of Latin America 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Administration Route - Percentage Breakdown of Value Sales for Oral Route, Injectable Route and Topical Route for the Years 2014, 2025 & 2030
  • TABLE 314: Rest of Latin America Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Indication - Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 315: Rest of Latin America Historic Review for Cutaneous and Systemic Leishmaniasis by Indication - Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 316: Rest of Latin America 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Indication - Percentage Breakdown of Value Sales for Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication for the Years 2014, 2025 & 2030
• MIDDLE EAST
  • Cutaneous and Systemic Leishmaniasis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
  • TABLE 317: Middle East Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 318: Middle East Historic Review for Cutaneous and Systemic Leishmaniasis by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 319: Middle East 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
  • TABLE 320: Middle East Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Drug Class - Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 321: Middle East Historic Review for Cutaneous and Systemic Leishmaniasis by Drug Class - Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 322: Middle East 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Drug Class - Percentage Breakdown of Value Sales for Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class for the Years 2014, 2025 & 2030
  • TABLE 323: Middle East Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 324: Middle East Historic Review for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 325: Middle East 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel for the Years 2014, 2025 & 2030
  • TABLE 326: Middle East Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Administration Route - Oral Route, Injectable Route and Topical Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 327: Middle East Historic Review for Cutaneous and Systemic Leishmaniasis by Administration Route - Oral Route, Injectable Route and Topical Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 328: Middle East 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Administration Route - Percentage Breakdown of Value Sales for Oral Route, Injectable Route and Topical Route for the Years 2014, 2025 & 2030
  • TABLE 329: Middle East Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Indication - Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 330: Middle East Historic Review for Cutaneous and Systemic Leishmaniasis by Indication - Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 331: Middle East 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Indication - Percentage Breakdown of Value Sales for Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication for the Years 2014, 2025 & 2030
• IRAN
  • TABLE 332: Iran Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Drug Class - Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 333: Iran Historic Review for Cutaneous and Systemic Leishmaniasis by Drug Class - Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 334: Iran 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Drug Class - Percentage Breakdown of Value Sales for Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class for the Years 2014, 2025 & 2030
  • TABLE 335: Iran Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 336: Iran Historic Review for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 337: Iran 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel for the Years 2014, 2025 & 2030
  • TABLE 338: Iran Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Administration Route - Oral Route, Injectable Route and Topical Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 339: Iran Historic Review for Cutaneous and Systemic Leishmaniasis by Administration Route - Oral Route, Injectable Route and Topical Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 340: Iran 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Administration Route - Percentage Breakdown of Value Sales for Oral Route, Injectable Route and Topical Route for the Years 2014, 2025 & 2030
  • TABLE 341: Iran Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Indication - Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 342: Iran Historic Review for Cutaneous and Systemic Leishmaniasis by Indication - Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 343: Iran 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Indication - Percentage Breakdown of Value Sales for Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication for the Years 2014, 2025 & 2030
• ISRAEL
  • TABLE 344: Israel Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Drug Class - Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 345: Israel Historic Review for Cutaneous and Systemic Leishmaniasis by Drug Class - Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 346: Israel 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Drug Class - Percentage Breakdown of Value Sales for Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class for the Years 2014, 2025 & 2030
  • TABLE 347: Israel Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 348: Israel Historic Review for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 349: Israel 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel for the Years 2014, 2025 & 2030
  • TABLE 350: Israel Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Administration Route - Oral Route, Injectable Route and Topical Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 351: Israel Historic Review for Cutaneous and Systemic Leishmaniasis by Administration Route - Oral Route, Injectable Route and Topical Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 352: Israel 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Administration Route - Percentage Breakdown of Value Sales for Oral Route, Injectable Route and Topical Route for the Years 2014, 2025 & 2030
  • TABLE 353: Israel Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Indication - Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 354: Israel Historic Review for Cutaneous and Systemic Leishmaniasis by Indication - Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 355: Israel 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Indication - Percentage Breakdown of Value Sales for Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication for the Years 2014, 2025 & 2030
• SAUDI ARABIA
  • TABLE 356: Saudi Arabia Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Drug Class - Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 357: Saudi Arabia Historic Review for Cutaneous and Systemic Leishmaniasis by Drug Class - Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 358: Saudi Arabia 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Drug Class - Percentage Breakdown of Value Sales for Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class for the Years 2014, 2025 & 2030
  • TABLE 359: Saudi Arabia Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 360: Saudi Arabia Historic Review for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 361: Saudi Arabia 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel for the Years 2014, 2025 & 2030
  • TABLE 362: Saudi Arabia Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Administration Route - Oral Route, Injectable Route and Topical Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 363: Saudi Arabia Historic Review for Cutaneous and Systemic Leishmaniasis by Administration Route - Oral Route, Injectable Route and Topical Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 364: Saudi Arabia 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Administration Route - Percentage Breakdown of Value Sales for Oral Route, Injectable Route and Topical Route for the Years 2014, 2025 & 2030
  • TABLE 365: Saudi Arabia Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Indication - Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 366: Saudi Arabia Historic Review for Cutaneous and Systemic Leishmaniasis by Indication - Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 367: Saudi Arabia 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Indication - Percentage Breakdown of Value Sales for Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication for the Years 2014, 2025 & 2030
• UNITED ARAB EMIRATES
  • TABLE 368: UAE Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Drug Class - Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 369: UAE Historic Review for Cutaneous and Systemic Leishmaniasis by Drug Class - Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 370: UAE 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Drug Class - Percentage Breakdown of Value Sales for Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class for the Years 2014, 2025 & 2030
  • TABLE 371: UAE Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 372: UAE Historic Review for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 373: UAE 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel for the Years 2014, 2025 & 2030
  • TABLE 374: UAE Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Administration Route - Oral Route, Injectable Route and Topical Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 375: UAE Historic Review for Cutaneous and Systemic Leishmaniasis by Administration Route - Oral Route, Injectable Route and Topical Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 376: UAE 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Administration Route - Percentage Breakdown of Value Sales for Oral Route, Injectable Route and Topical Route for the Years 2014, 2025 & 2030
  • TABLE 377: UAE Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Indication - Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 378: UAE Historic Review for Cutaneous and Systemic Leishmaniasis by Indication - Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 379: UAE 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Indication - Percentage Breakdown of Value Sales for Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication for the Years 2014, 2025 & 2030
• REST OF MIDDLE EAST
  • TABLE 380: Rest of Middle East Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Drug Class - Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 381: Rest of Middle East Historic Review for Cutaneous and Systemic Leishmaniasis by Drug Class - Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 382: Rest of Middle East 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Drug Class - Percentage Breakdown of Value Sales for Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class for the Years 2014, 2025 & 2030
  • TABLE 383: Rest of Middle East Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 384: Rest of Middle East Historic Review for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 385: Rest of Middle East 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel for the Years 2014, 2025 & 2030
  • TABLE 386: Rest of Middle East Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Administration Route - Oral Route, Injectable Route and Topical Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 387: Rest of Middle East Historic Review for Cutaneous and Systemic Leishmaniasis by Administration Route - Oral Route, Injectable Route and Topical Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 388: Rest of Middle East 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Administration Route - Percentage Breakdown of Value Sales for Oral Route, Injectable Route and Topical Route for the Years 2014, 2025 & 2030
  • TABLE 389: Rest of Middle East Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Indication - Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 390: Rest of Middle East Historic Review for Cutaneous and Systemic Leishmaniasis by Indication - Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 391: Rest of Middle East 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Indication - Percentage Breakdown of Value Sales for Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication for the Years 2014, 2025 & 2030
• AFRICA
  • Cutaneous and Systemic Leishmaniasis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
  • TABLE 392: Africa Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Drug Class - Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 393: Africa Historic Review for Cutaneous and Systemic Leishmaniasis by Drug Class - Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 394: Africa 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Drug Class - Percentage Breakdown of Value Sales for Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class for the Years 2014, 2025 & 2030
  • TABLE 395: Africa Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 396: Africa Historic Review for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 397: Africa 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel for the Years 2014, 2025 & 2030
  • TABLE 398: Africa Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Administration Route - Oral Route, Injectable Route and Topical Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 399: Africa Historic Review for Cutaneous and Systemic Leishmaniasis by Administration Route - Oral Route, Injectable Route and Topical Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 400: Africa 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Administration Route - Percentage Breakdown of Value Sales for Oral Route, Injectable Route and Topical Route for the Years 2014, 2025 & 2030
  • TABLE 401: Africa Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Indication - Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 402: Africa Historic Review for Cutaneous and Systemic Leishmaniasis by Indication - Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 403: Africa 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Indication - Percentage Breakdown of Value Sales for Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication for the Years 2014, 2025 & 2030

IV. COMPETITION